These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35331406)

  • 1. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
    Ferreira JP; Butler J; Zannad F; Filippatos G; Schueler E; Steubl D; Zeller C; Januzzi JL; Pocock S; Packer M; Anker SD
    J Am Coll Cardiol; 2022 Mar; 79(12):1129-1137. PubMed ID: 35331406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
    Ferreira JP; Zannad F; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Jamal W; Steubl D; Schueler E; Packer M
    J Am Coll Cardiol; 2021 Mar; 77(11):1397-1407. PubMed ID: 33736821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
    Ferreira JP; Zannad F; Butler J; Filipattos G; Ritter I; Schüler E; Kraus BJ; Pocock SJ; Anker SD; Packer M
    Eur Heart J; 2022 Aug; 43(31):2984-2993. PubMed ID: 35687107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
    Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B; Nordaby M; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Lancet Diabetes Endocrinol; 2022 Jan; 10(1):35-45. PubMed ID: 34861154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Bhm M; Anker S; Mahfoud F; Lauder L; Filippatos G; Ferreira JP; Pocock SJ; Brueckmann M; Saloustros I; Schler E; Wanner C; Zannad F; Packer M; Butler J
    Eur Heart J; 2023 Feb; 44(5):396-407. PubMed ID: 36478225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Butler J; Filippatos G; Jamal Siddiqi T; Brueckmann M; Böhm M; Chopra VK; Pedro Ferreira J; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Shah SJ; Senni M; Vedin O; Verma S; Peil B; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Jan; 145(3):184-193. PubMed ID: 34779658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    Anker SD; Butler J; Filippatos G; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure-Valenzuela E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Carson P; Lam CSP; Marx N; Zeller C; Sattar N; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    N Engl J Med; 2021 Oct; 385(16):1451-1461. PubMed ID: 34449189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
    Filippatos G; Butler J; Farmakis D; Zannad F; Ofstad AP; Ferreira JP; Green JB; Rosenstock J; Schnaidt S; Brueckmann M; Pocock SJ; Packer M; Anker SD;
    Circulation; 2022 Aug; 146(9):676-686. PubMed ID: 35762322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
    Shen L; Kristensen SL; Bengtsson O; Böhm M; de Boer RA; Docherty KF; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez MFA; O'Meara E; Nicolau JC; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV
    JACC Heart Fail; 2021 Apr; 9(4):254-264. PubMed ID: 33549554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction.
    Suzuki S; Motoki H; Kanzaki Y; Maruyama T; Hashizume N; Kozuka A; Yahikozawa K; Kuwahara K
    ESC Heart Fail; 2020 Oct; 7(5):2752-2761. PubMed ID: 32592265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
    Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
    Doehner W; Anker SD; Butler J; Zannad F; Filippatos G; Ferreira JP; Salsali A; Kaempfer C; Brueckmann M; Pocock SJ; Januzzi JL; Packer M
    Eur Heart J; 2022 Sep; 43(36):3435-3446. PubMed ID: 35788657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
    Butler J; Filippatos G; Siddiqi TJ; Ferreira JP; Brueckmann M; Bocchi E; Böhm M; Chopra VK; Giannetti N; Iwata T; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Rauch-Kröhnert U; Shah SJ; Senni M; Sumin M; Verma S; Zhang J; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Oct; 146(14):1046-1055. PubMed ID: 36098051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
    Ferreira JP; Zannad F; Butler J; Filippatos G; Pocock SJ; Brueckmann M; Steubl D; Schueler E; Anker SD; Packer M
    JAMA Cardiol; 2022 Nov; 7(11):1148-1159. PubMed ID: 36129693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs.
    Ferreira JP; Pitt B; McMurray JJV; Pocock SJ; Solomon SD; Pfeffer MA; Zannad F; Rossignol P
    JACC Heart Fail; 2022 Nov; 10(11):842-850. PubMed ID: 36328653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
    Böhm M; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Abdin A; Mahfoud F; Brueckmann M; Gollop ND; Iwata T; Ponikowski P; Wanner C; Zannad F; Packer M; Anker SD;
    J Am Coll Cardiol; 2022 Jul; 80(1):1-18. PubMed ID: 35772911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US.
    Talha KM; Butler J; Greene SJ; Aggarwal R; Anker SD; Claggett BL; Solomon SD; McMurray JJV; Vaduganathan M; Fonarow GC
    JAMA Cardiol; 2023 Jan; 8(1):66-73. PubMed ID: 36334258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
    Packer M; Butler J; Zannad F; Filippatos G; Ferreira JP; Pocock SJ; Carson P; Anand I; Doehner W; Haass M; Komajda M; Miller A; Pehrson S; Teerlink JR; Schnaidt S; Zeller C; Schnee JM; Anker SD
    Circulation; 2021 Oct; 144(16):1284-1294. PubMed ID: 34459213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.